Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Progression‐free survival · women with recurrent epithelial ovarian cancer

175 mg/m2 paclitaxel showed no clear difference in progression‐free survival compared with 250 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 1.07 [0.88, 1.3]
1 study · 330 participants
Low

Progression‐free survival · women with recurrent epithelial ovarian cancer

135 mg/m2 paclitaxel showed no clear difference in progression‐free survival compared with 175 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 1.09 [0.94, 1.28]
1 study · 407 participants
Low